WO2005079772A3 - Combination of (s)-amlodipine and an ace inhibitor, and methods for reducing hypertension - Google Patents

Combination of (s)-amlodipine and an ace inhibitor, and methods for reducing hypertension Download PDF

Info

Publication number
WO2005079772A3
WO2005079772A3 PCT/US2005/004460 US2005004460W WO2005079772A3 WO 2005079772 A3 WO2005079772 A3 WO 2005079772A3 US 2005004460 W US2005004460 W US 2005004460W WO 2005079772 A3 WO2005079772 A3 WO 2005079772A3
Authority
WO
WIPO (PCT)
Prior art keywords
amlodipine
ace inhibitor
preferred
methods
combination
Prior art date
Application number
PCT/US2005/004460
Other languages
French (fr)
Other versions
WO2005079772A2 (en
Inventor
Larry Bush
Donna Roy Grogan
Original Assignee
Sepracor Inc
Larry Bush
Donna Roy Grogan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc, Larry Bush, Donna Roy Grogan filed Critical Sepracor Inc
Publication of WO2005079772A2 publication Critical patent/WO2005079772A2/en
Publication of WO2005079772A3 publication Critical patent/WO2005079772A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention generally relates to pharmaceutical compositions comprising optically pure (S)-amlodipine and an ACE inhibitor. In a preferred embodiment the (S)-­amlodipine is (S)-amlodipine-L-malate, or a polymorph, pseudopolymorph or solvate thereof. In a preferred embodiment, the ACE inhibitor is ramipril. The pharmaceutical compositions of the invention are useful in the treatment of hypertension. The present invention also relates to a method of treating a patient suffering from hypertension or a cardiac disorder, comprising co-administering a therapeutically effective amount of optically pure (S)-amlodipine and an ACE inhibitor. In a preferred embodiment the (S)­-amlodipine is (S)-amlodipine-L-malate, or a polymorph, pseudopolymorph or solvate thereof. In a preferred embodiment, the ACE inhibitor is ramipril.
PCT/US2005/004460 2004-02-18 2005-02-14 Combination of (s)-amlodipine and an ace inhibitor, and methods for reducing hypertension WO2005079772A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US54545104P 2004-02-18 2004-02-18
US60/545,451 2004-02-18
US55403004P 2004-03-16 2004-03-16
US60/554,030 2004-03-16
US64963505P 2005-02-03 2005-02-03
US60/649,635 2005-02-03

Publications (2)

Publication Number Publication Date
WO2005079772A2 WO2005079772A2 (en) 2005-09-01
WO2005079772A3 true WO2005079772A3 (en) 2005-11-03

Family

ID=34891140

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/004460 WO2005079772A2 (en) 2004-02-18 2005-02-14 Combination of (s)-amlodipine and an ace inhibitor, and methods for reducing hypertension

Country Status (1)

Country Link
WO (1) WO2005079772A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2790817A1 (en) 2010-02-24 2011-09-01 Sanofi-Aventis Deutschland Gmbh Solid pharmaceutical formulations of ramipril and amlodipine besylate, and their preparation
CN102370965A (en) * 2010-08-11 2012-03-14 南京先宇科技有限公司 Pharmaceutical composition containing pharmaceutically acceptable salts of levoamlodipine and pharmaceutically acceptable salts of perindopril
US10799453B2 (en) 2018-04-11 2020-10-13 Silvergate Pharmaceuticals, Inc. Amlodipine formulations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020072532A1 (en) * 1998-11-04 2002-06-13 Foster Robert T. Methods of pharmacological treatment using S (-) amlodipine
WO2002049645A1 (en) * 2000-12-18 2002-06-27 Novartis Ag Therapeutic combination of amlodipine and benazepril

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020072532A1 (en) * 1998-11-04 2002-06-13 Foster Robert T. Methods of pharmacological treatment using S (-) amlodipine
WO2002049645A1 (en) * 2000-12-18 2002-06-27 Novartis Ag Therapeutic combination of amlodipine and benazepril

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FOGARI R ET AL: "Effect of benazepril amlodipine combination on fibrinolysis in hypertensive diabetic patients", EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, SPRINGER VERLAG, DE, vol. 59, no. 4, August 2003 (2003-08-01), pages 271 - 275, XP002319854, ISSN: 0031-6970 *
FOGARI R, PRETI P, ZOPPI A, RINALDI A, CORRADI L, PASOTTI C, POLETTI L, MARASI G-L, DEROSA G, MUGELLINI A, VOGLINI C, LAZZARI P: "Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients", AMERICAN JOURNAL OF HYPERTENSION, vol. 15, no. 12, December 2002 (2002-12-01), pages 1042 - 1049, XP002339215 *
JEFFERY TRINA K; WANSTALL JANET C: "Pulmonary vascular remodelling in hypoxic rats: Effects of amlodipine, alone and with perindopril", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 416, no. 1-2, 23 March 2001 (2001-03-23), pages 123 - 131, XP002339216 *
KOHLMANN OSVALDO: "Efficacy and tolerability of the Amlodipine+Enalapril fixed combination therapy in the treatment of broad population of stage I and II essential hypertension", AMERICAN JOURNAL OF HYPERTENSION, vol. 16, no. 5/2, May 2003 (2003-05-01), pages 120A - 121A, XP002339214 *
MITAL SEEMA; LOKE KIT E; SLATER JAMES P; ADDONIZIO LINDA; GERSONY WELTON M; HINTZE THOMAS H: "Synergy of amlodipine and angiotensin-converting enzyme inhibitors in regulating myocardial oxygen consumption in normal canine and failing human hearts", AMERICAN JOURNAL OF CARDIOLOGY, vol. 83, no. 12A, 17 June 1999 (1999-06-17), pages 92H - 98H, XP002339217 *

Also Published As

Publication number Publication date
WO2005079772A2 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
EP2153832A3 (en) Heterocyclic aspartyl protease inhibitors
WO2003032914A3 (en) Methods for treating substance abuse with cholinesterase inhibitors
WO2006065277A3 (en) Heterocyclic aspartyl protease inhibitors
EP1583534A4 (en) 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004100868A3 (en) Method of treating transplant rejection
WO2004050022A8 (en) Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
CA2504735A1 (en) Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004034988A3 (en) Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
WO2002058734A3 (en) Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
WO2004043341A3 (en) Treatment for hemorrhagic shock
AU2004208615B2 (en) Medicine for prevention of and treatment for arteriosclerosis and hypertension
WO2008039829A3 (en) Diphenylheterocycle cholesterol absorption inhibitors
WO2007056324A3 (en) Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent
WO2004017948A3 (en) Use of lck inhibitor for treatment of immunologic diseases
WO2005030187A3 (en) Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
WO2006052899A3 (en) Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders
WO2003092606A3 (en) Cholinesterase inhibitors to prevent injuries caused by chemicals
WO2002058685A3 (en) Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
WO2006017823A3 (en) Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors
WO2005079772A3 (en) Combination of (s)-amlodipine and an ace inhibitor, and methods for reducing hypertension
TNSN07038A1 (en) Methods for improving bioavailability of a renin inhibitor
WO2005081972A3 (en) Maleiimide anti-tumor phosphatase inhibitors
WO2002064160A8 (en) Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
NO20042758L (en) Procedure for treating a patient requiring analgesia.
AU2003273762A1 (en) Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase